An unexpected role for a Wnt-inhibitor: Dickkopf-1 triggers a novel cancer survival mechanism through modulation of aldehyde-dehydrogenase-1 activity

Cell Death and Disease

Volumn 5, Issue 2, 2014, Pages

  Krause, U ^a,b   Ryan, D M ^c   Clough, B H ^a   Gregory, C A ^a  

^a Texas A and M Medical School   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

ALDH1; Dkk 1; MOS J; osteosarcoma; Wnt signaling

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; DICKKOPF 1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEIN C JUN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; CANCER SURVIVAL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; METABOLIC STRESS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; WNT SIGNALING PATHWAY;

ANIMALS; BINDING SITES; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 4; MICE; MICE, NUDE; OSTEOGENESIS; OSTEOLYSIS; OSTEOSARCOMA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-JUN; RETINAL DEHYDROGENASE; RHO GTP-BINDING PROTEINS; STRESS, PHYSIOLOGICAL; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; WNT SIGNALING PATHWAY;

EID: 84896750356     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.67     Document Type: Article

References (56)

1. Arndt CA, Rose PS, Folpe AL, Laack NN. Common musculoskeletal tumors of childhood and adolescence. Mayo Clin Proc 2012; 87: 475-487.
2. Gregory CA, Reyes E, Whitney MJ, Spees JL. Enhanced engraftment of mesenchymal stem cells in a cutaneous wound model by culture in allogenic species-specific serum and administration in fibrin constructs. Stem Cells 2006; 24: 2232-2243.
3. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004; 341: 19-39.
4. Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8: 751-764.
5. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494.
6. Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R et al. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 2007; 97: 1552-1559.
7. Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008; 68: 1396-1404.
8. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clezardin P et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007; 97: 964-970.
9. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311-320.
10. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 2010; 220: 24-33.
11. Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007; 117: 3248-3257.
12. Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL et al. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate 2011; 71: 615-625.
13. Guo Y, Rubin EM, Xie J, Zi X, Hoang BH. Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res 2008; 466: 2039-2045.
14. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009; 119: 837-851.
15. Navarro D, Agra N, Pestana A, Alonso J, Gonzalez-Sancho JM. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes betacatenin/ TCF-mediated transcription. Carcinogenesis 2010; 31: 394-401.
16. Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther 2010; 9: 731-741.
17. Joliat MJ, Umeda S, Lyons BL, Lynes MA, Shultz LD. Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma. In Vivo 2002; 16: 223-228.
18. Gregory CA, Singh H, Perry AS, Prockop DJ. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem 2003; 278: 28067-28078.
19. Bain G, Muller T, Wang X, Papkoff J. Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun 2003; 301: 84-91.
20. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003; 18: 1842-1853.
21. Zeitouni S, Krause U, Clough BH, Halderman H, Falster A, Blalock DT et al. Human mesenchymal stem cell-derived matrices for enhanced osteoregeneration. Sci Transl Med 2012; 4: 132ra155.
22. Gregory CA, Gunn WG, Peister A, Prockop DJ. An Alizarin red-based assay of mineralization by adherent cells in culture: Comparison with cetylpyridinium chloride extraction. Anal Biochem 2004; 329: 77-84.
23. Makia NL, Bojang P, Falkner KC, Conklin DJ, Prough RA. Murine hepatic aldehyde dehydrogenase 1a1 is a major contributor to oxidation of aldehydes formed by lipid peroxidation. Chem Biol Interact 2011; 191: 278-287.
24. Vasiliou V, Nebert DW. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics 2005; 2: 138-143.
25. Kast RE, Belda-Iniesta C. Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: An hypothesis. Curr Stem Cell Res Ther 2009; 4: 314-317.
26. Moreb JS, Ucar D, Han S, Amory JK, Goldstein AS, Ostmark B et al. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact 2012; 195: 52-60.
27. Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C et al. A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res 2010; 70: 5963-5973.
28. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009; 5: 100-107.
29. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461: 614-620.
30. Shultz MD, Kirby CA, Stams T, Chin DN, Blank J, Charlat O et al. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: Antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J Med Chem 2012; 55: 1127-1136.
31. Pandur P, Maurus D, Kuhl M. Increasingly complex: New players enter the Wnt signaling network. Bioessays 2002; 24: 881-884.
32. Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N et al. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun 2004; 323: 1246-1250.
33. Sun TQ, Lu B, Feng JJ, Reinhard C, Jan YN, Fantl WJ et al. PAR-1 is a Dishevelledassociated kinase and a positive regulator of Wnt signalling. Nat Cell Biol 2001; 3: 628-636.
34. Yan D, Wallingford JB, Sun TQ, Nelson AM, Sakanaka C, Reinhard C et al. Cell autonomous regulation of multiple Dishevelled-dependent pathways by mammalian Nkd. Proc Natl Acad Sci USA 2001; 98: 3802-3807.
35. Tao YM, Liu Z, Liu HL. Dickkopf-1 (DKK1) promotes invasion and metastasis of hepatocellular carcinoma. Dig Liver Dis 2013; 45: 251-257.
36. Makia NL, Amunom I, Falkner KC, Conklin DJ, Surapureddi S, Goldstein JA et al. Activator protein-1 regulation of murine aldehyde dehydrogenase 1a1. Mol Pharmacol 2012; 82: 601-613.
37. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol 2007; 19: 142-149.
38. Wang J, Xia Y. Assessing developmental roles of MKK4 and MKK7 in vitro. Commun Integr Biol 2012; 5: 319-324.
39. Habas R, Dawid IB, He X. Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastrulation. Genes Dev 2003; 17: 295-309.
40. Schlessinger K, Hall A, Tolwinski N. Wnt signaling pathways meet Rho GTPases. Genes Dev 2009; 23: 265-277.
41. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192-1205.
42. Killick R, Ribe EM, Al-Shawi R, Malik B, Hooper C, Fernandes C et al. Clusterin regulates beta-Amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol Psychiatry 2014; 19: 88-98.
43. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69: 1302-1313.
44. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
45. Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 2010; 24: 501-505.
46. Wang L, Park P, Zhang H, La Marca F, Lin CY. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 2011; 128: 294-303.
47. Alnouti Y, Klaassen CD. Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice. Toxicol Sci 2008; 101: 51-64.
48. Gibault L, Perot G, Chibon F, Bonnin S, Lagarde P, Terrier P et al. New insights in sarcoma oncogenesis: A comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol 2011; 223: 64-71.
49. Fritchie KJ, Goldblum JR, Tubbs RR, Sun Y, Carver P, Billings SD et al. The expanded histologic spectrum of myxoid liposarcoma with an emphasis on newly described patterns: Implications for diagnosis on small biopsy specimens. Am J Clin Pathol 2012; 137: 229-239.
50. Menezes ME, Devine DJ, Shevde LA, Samant RS. Dickkopf1: A tumor suppressor or metastasis promoter? Int J Cancer 2012; 130: 1477-1483.
51. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 2000; 18: 261-271.
52. Krause U, Harris S, Green A, Ylostalo J, Zeitouni S, Lee N et al. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc Natl Acad Sci USA 2010; 107: 4147-4152.
53. Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 2010; 285: 40135-40147.
54. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy Jr. JD. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106-2111.
55. Gregory CA, Perry AS, Reyes E, Conley A, Gunn WG, Prockop DJ. Dkk-1-derived synthetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow. J Biol Chem 2005; 280: 2309-2323.
56. Gunn WG, Krause U, Lee N, Gregory CA. Pharmaceutical inhibition of glycogen synthetase kinase-3beta reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood 2011; 117: 1641-1651.